UBS Group AG Acquires New Stake in Billiontoone, Inc. $BLLN

UBS Group AG acquired a new stake in Billiontoone, Inc. (NASDAQ:BLLN) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 31,599 shares of the company’s stock, valued at approximately $2,586,000.

Several other hedge funds have also recently added to or reduced their stakes in BLLN. Baillie Gifford & Co. acquired a new position in Billiontoone in the 4th quarter valued at $103,786,000. Massachusetts Financial Services Co. MA acquired a new position in Billiontoone in the 4th quarter valued at $13,373,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Billiontoone in the 4th quarter valued at $1,348,000. FNY Investment Advisers LLC acquired a new position in Billiontoone in the 4th quarter valued at $497,000. Finally, Green Alpha Advisors LLC acquired a new position in Billiontoone in the 4th quarter valued at $436,000.

Billiontoone Trading Down 1.6%

Shares of NASDAQ:BLLN opened at $84.52 on Wednesday. The business’s 50-day simple moving average is $81.95. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The firm has a market cap of $3.89 billion and a P/E ratio of 153.67. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $138.70.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The business had revenue of $108.39 million for the quarter, compared to analyst estimates of $95.81 million. The firm’s revenue for the quarter was up 83.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.39) earnings per share. As a group, equities research analysts predict that Billiontoone, Inc. will post 0.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on BLLN shares. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Friday, May 15th. Wells Fargo & Company cut their target price on Billiontoone from $110.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday, March 5th. BTIG Research cut their target price on Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, May 7th. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Finally, JPMorgan Chase & Co. raised their target price on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $125.29.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.